Science        
2 November 2012 vol 338, issue 6107, pages 569-712
http://www.sciencemag.org/current.dtl

Policy Forum – Public Health
Optimizing Investments in Malaria Treatment and Diagnosis
Justin M. Cohen, Aaron M. Woolsey, Oliver J. Sabot, Peter W. Gething, Andrew J. Tatem, and Bruno Moonen
Science 2 November 2012: 612-614.

Better targeting of antimalarials to people who need them will maximize the impact of interventions in the private sector.

Summary
The Roll Back Malaria (RBM) Partnership has set an ambitious target of achieving near zero deaths from malaria by 2015 (1). Scale-up of insecticide-treated nets, indoor residual spraying of insecticide, and increased access to treatment with artemisinin-based combination therapies (ACTs) over the past decade have led to reductions in malaria incidence of more than 50% in 43 countries, including 8 in Africa (2). However, as an estimated 655,000 malaria deaths still occurred in 2010 (2), with the great majority in sub-Saharan Africa, substantial challenges remain.